LL-37 cathelicidin is the only human antimicrobial peptide of its class — a 37-amino-acid molecule produced by immune cells, skin, and mucosal surfaces. Research supported by TelosRX's licensed providers shows it has studied roles in wound repair, immune regulation, and skin defense. Compounded LL-37 is not FDA-approved.
Most people encounter LL-37 only when they go looking for something to help their body repair. It turns out their body already makes it — just not always in sufficient quantities, particularly at wound sites or under chronic inflammation.
Here is what peer-reviewed research actually shows about this peptide.
What Is LL-37 Cathelicidin?
LL-37 is the C-terminal fragment of hCAP18, a protein encoded by the CAMP gene. Its name reflects its structure: it begins with two leucine residues and spans 37 amino acids.
It is classified as a cathelicidin — a family of host-defense peptides found across vertebrate species. Humans produce only one: LL-37. When it is absent or suppressed, the body's frontline defense at epithelial surfaces weakens.
Natural production sites include:
- Neutrophils (white blood cells deployed to wound sites)
- Epithelial cells of the skin, airways, and gut lining
- Macrophages (activation is stimulated by vitamin D signaling)
- Platelets at sites of active injury
How LL-37 Works: Mechanisms in Research
LL-37 operates through several distinct mechanisms depending on the tissue environment:
Direct antimicrobial activity: LL-37 inserts into bacterial membranes using a "carpet model" — coating the membrane surface until it collapses. At sufficient concentrations, it disrupts biofilms that standard antibiotics cannot penetrate.
Wound healing signaling: A landmark 2007 study in PubMed established that LL-37 activates EGFR-mediated signaling via metalloproteinase cleavage, driving keratinocyte migration and epithelial proliferation — core steps in skin closure after injury.
Immune modulation: LL-37 recruits neutrophils and macrophages, triggers dendritic cell maturation, and regulates cytokine release. It does not simply amplify inflammation — it coordinates it toward resolution.
Angiogenesis: Research has documented LL-37-driven blood vessel formation at wound sites, critical for delivering oxygen and nutrients to healing tissue.
LL-37 Research: Wound Healing Evidence
Wound healing is the most clinically developed research area for LL-37. Two phases of randomized controlled trials evaluated topical LL-37 in chronic venous leg ulcers:
A Phase I/IIa trial (topical LL-37 in 34 patients with chronic venous ulcers) found healing rate constants approximately 6-fold higher at 0.5 mg/mL and 3-fold higher at 1.6 mg/mL compared to placebo.
A Phase IIb trial (148 patients) found complete wound closure in 28.1% of LL-37-treated large wounds versus 8.1% in the placebo group. A 2026 review in European Journal of Pharmacology (ScienceDirect 2026) confirmed these wound healing mechanisms extend across cathelicidin analogs.
Separate research identified that LL-37 is deficient in chronic wound tissue — its absence may actively impair re-epithelialization. Replenishment via exogenous LL-37 could address this deficit directly.
For patients managing tendon or joint issues alongside immune support, our guide to peptides for tendon repair covers complementary options including BPC-157 and TB-500.
LL-37 Research: Antimicrobial and Biofilm Defense
A 2021 PMC study tested LL-37 efficacy in an MRSA wound infection mouse model. LL-37-treated animals showed significantly reduced bacterial burden and improved wound closure compared to controls — a finding relevant given rising antibiotic resistance in clinical settings.
LL-37 also disrupts biofilms — bacterial communities embedded in a protective matrix that resist most antibiotics. LL-37's membrane-disrupting mechanism bypasses that defense entirely.
LL-37 Research: Skin Inflammation
LL-37 has a bidirectional relationship with skin inflammation. It is overexpressed in psoriasis (contributing to the inflammatory cascade) yet deficient in eczema (impairing barrier defense). This makes it a subject of ongoing research for immune-mediated skin conditions.
Preclinical research has examined LL-37 in rosacea and cutaneous wound models, with generally favorable findings on barrier restoration. For the broader immunology context, see our LL-37 antimicrobial research overview.
LL-37 Research: Gut Barrier Protection
Epithelial cells lining the gut produce LL-37 as part of the mucosal immune barrier. Preclinical research in inflammatory bowel disease models has documented LL-37's role in modulating mucosal inflammation and preserving barrier integrity.
Human gut microbiome studies link low LL-37 expression to increased intestinal permeability, though direct clinical interventions remain in early stages. This is an area of growing research interest, not yet established clinical therapy.
LL-37 Dosing in Published Research
There is no FDA-approved dosage for LL-37. The following reflects concentrations used in published studies. Any protocol involving LL-37 is subject to medical approval by a licensed provider.
| Route | Dose Used in Research | Context |
|---|---|---|
| Topical | 0.5–1.6 mg/mL, twice weekly | Venous leg ulcer Phase I/IIa and IIb trials |
| Subcutaneous | 0.05–0.1 mg, 2–3x weekly | Immune modulation protocols in research settings |
| Subcutaneous (wound) | 100–200 mcg/day | Wound healing protocols in animal and early human studies |
Higher topical concentrations (≥3.2 mg/mL) showed no additional benefit and may impair keratinocyte viability — a dose-response ceiling that researchers have identified as an important boundary.
LL-37 Safety Profile: What the Data Shows
Topical LL-37 at Phase IIa/IIb trial doses was well tolerated, with no serious adverse events attributable to the peptide among enrolled patients.
At very high concentrations, LL-37 shows cytotoxic effects on mammalian cells in vitro — expected behavior from a membrane-disrupting peptide, concentration-dependent, and not a risk at therapeutic research doses.
Parenteral (injection) use in humans is less clinically characterized than topical administration. Systemic immune activation is theoretically possible. This is part of why licensed provider review is essential before any LL-37 protocol.
Compounded LL-37 is not FDA-approved and is prepared under federal compounding regulations. Access at TelosRX is subject to asynchronous evaluation and approval by a licensed provider. For a related immune peptide, see our article on Thymosin Alpha-1 immune research.
Who Might Consider LL-37?
Current research interest centers on individuals with:
- Chronic wounds or impaired tissue repair
- Recurrent infections or compromised mucosal defense
- Immune modulation goals within a broader longevity or recovery protocol
- Skin conditions where barrier defense is a factor
LL-37 is not FDA-approved for any clinical indication. It is an investigational research peptide. Whether it fits your goals requires individual provider evaluation — which is how all TelosRX protocols begin.
Frequently Asked Questions
What is LL-37 cathelicidin used for in research?
Published research has studied LL-37 for wound healing, antimicrobial defense (including against MRSA), biofilm disruption, immune modulation, gut barrier support, and skin inflammation. It is not FDA-approved for any of these applications. All access at TelosRX involves compounded peptide subject to licensed provider review.
Is LL-37 a steroid or antibiotic?
Neither. LL-37 is an endogenous antimicrobial peptide produced by your own immune cells and epithelial tissue. It is not a steroid and does not suppress the immune system. Its antibacterial mechanism is physical membrane disruption, distinct from how antibiotics work biochemically.
How does LL-37 compare to BPC-157 for wound healing?
LL-37 primarily targets infection defense and re-epithelialization; BPC-157 primarily drives angiogenesis and collagen organization. Both are in preclinical to early-stage clinical research. They address different phases of repair and may complement each other in provider-designed protocols.
Does LL-37 have side effects?
At research-level topical doses, LL-37 was well tolerated in Phase IIa and IIb trials with no serious peptide-attributable adverse events. High concentrations show cytotoxicity in vitro. Systemic injection use is less characterized. Individual response varies; all use requires licensed provider oversight.
Is LL-37 FDA-approved?
No. LL-37 is not FDA-approved for any indication. Compounded LL-37 is prepared under federal compounding regulations and is subject to evaluation by a licensed provider before access through TelosRX. It is an investigational peptide studied in clinical and preclinical settings.
How does vitamin D relate to LL-37 levels?
Vitamin D directly upregulates the CAMP gene, which encodes hCAP18 — the precursor protein to LL-37. This is one mechanism through which vitamin D supports immune function at mucosal barriers. Research has documented this regulatory axis in respiratory, gut, and skin tissue.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.